Business Wire

Toshiba's e-STUDIO5005AC Earns Buyers Laboratory's "Highly Recommended" and "Highly Reliable"

Del

Toshiba Tec Corporation (TOKYO:6588) today announced that its latest colour Multi-function peripherals (MFP), the e-STUDIO5005AC received the Buyers Laboratory LLC’s (BLI) “Highly Recommended” and “Highly Reliable” rating. BLI is the leading independent analytical information provider, and from its two-month, 210,000 impression durability test, the company's award-winning MFP performed extremely well in reliability, ease of use and security features.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161225005001/en/

Toshiba Tec Corporation announced that its latest colour Multi-function peripherals (MFP), the e-STU ...

Toshiba Tec Corporation announced that its latest colour Multi-function peripherals (MFP), the e-STUDIO5005AC received the Buyers Laboratory LLC's (BLI) "Highly Recommended" and "Highly Reliable" rating. (Graphic: Business Wire)

The leading independent analytics provider noted the e-STUDIO5005AC’s ideal fit for medium- to large-size workgroups. The recent addition to Toshiba’s award-winning e-STUDIO line also scored high within nine other BLI testing categories including user maintenance, productivity and image quality.

“The Toshiba e-STUDIO5005AC promises to deliver maximum uptime for mid-size to large workgroups, thanks to outstanding reliability and simple procedures for replacing toner, drums and the waste toner container,” said BLI Senior Editor George Mikolay. “In addition, the device’s fast job stream speeds mean it will have no problem remaining productive in environments in which multiple users send multiple types of jobs over the course of the day. And those long-run jobs will not be at the expense of image quality, which proved to be consistent throughout testing and will meet the needs of most business environments.”

They were further impressed by e-STUDIO5005AC’s features of productivity and ease of use: boost scan productivity with fast scan speeds and 300-sheet duplex single-pass feeder, increase office efficiency with Simple Scan and Simple Copy menus by its new user interface, and take advantage of allowing applications to be embedded on to the MFP by the newly introduced e-BRIDGE Next controller.

Moreover, BLI noted that Toshiba’s self-encrypting hard drive with automatic drive invalidation and data overwrite up to 15 times*, and passing the strict U.S. Federal Information processing Standard 140-2, making the MFP ideal for any organization seeking to bolster its data security.

“It is a great honour for us to receive such an evaluation from the most reliable organization,” said Isao Sugehara, Chief Marketing Executive of Toshiba Tec Printing Solutions Business Group. “We believe this is the result that e-STUDIO5005AC has fulfilled all of the necessary needs and offers value for customers. This was achieved by everyone who dedicated to introduce this product”.

* The availability vary from country to country

About Buyers Laboratory LLC

Buyers Laboratory LLC (BLI) is the world's leading independent provider of analytical information and testing services to the document management industry. For over 50 years, buyers have relied on BLI to help them differentiate products' strengths and weaknesses and make the best purchasing decisions, while industry sales, marketing and product professionals have turned to BLI for insightful competitive intelligence and valued guidance on product development, competitive positioning and sales channel and marketing support. BLI also offers private, for-hire testing services that help manufacturers develop and market better products and consumables.

About Toshiba Tec

Toshiba Tec Corporation is a Toshiba’s group company, a leading provider of technology solutions, operating across multiple industries – ranging from retail, education and business services to hospitality and manufacturing. With headquarters in Japan and over 80 subsidiaries worldwide, Toshiba Tec Corporation helps organizations transform the way they create, record, share, manage and display information.

Please visit http://www.toshibatec.co.jp/en/
For Global site please visit http://www.toshibatec.com/global/

Unless otherwise specified and/or credited all images, artwork, text and graphics, logos and logotypes are the copyright and/or trademark of the respective owners. All rights reserved.

Contact information

Media Contact
Toshiba Tec Corporation
Toshihiko “Tommy” Minato, +81-(0)50-3681-5528
Marketing Department
Products, Marketing & Service Division
Printing Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33Pressemelding

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

CTS Engines Announces Senior Management Hire12.12.2017 13:00Pressemelding

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00Pressemelding

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom